The FDA has approved Tyzavan, a novel ready-to-infuse, room temperature stable formulation of vancomycin, for the treatment of various bacterial infections.

University of Wisconsin–Madison–led researchers report lower yet statistically non-significant recurrence of Clostridioides ...